局限性胰腺神经内分泌癌的手术与辅助化疗生存分析
本研究基于美国国家癌症数据库2004至2017年数据,纳入199例局限性小细胞和大细胞胰腺神经内分泌癌患者,评估手术切除与围术期化疗对总生存的影响。结果显示50.3%患者接受切除,切除组中位总生存29.4个月优于未切除组的8.6个月,多因素分析示切除与生存改善相关(aHR 0.58,95%CI 0.37-0.92),而辅助化疗未见显著获益。
要点
- 局限性胰腺神经内分泌癌切除组中位总生存29.4个月,未切除组8.6个月。
- 多因素分析示切除与生存改善独立相关(aHR 0.58,95%CI 0.37-0.92)。
- 辅助化疗在本研究中未显示与生存改善的独立关联。
核心结论
- 对于局限性胰腺神经内分泌癌,手术切除与改善的总生存相关。
- 辅助化疗的作用尚需进一步研究。
研究设计与样本
- 回顾性队列研究,数据来源于美国国家癌症数据库2004至2017年。
- 纳入199例局限性(cT1-3,M0)小细胞和大细胞胰腺神经内分泌癌患者。
- 采用Kaplan-Meier估计和Cox回归模型分析生存。
主要发现
- 50.3%的患者接受了切除,切除患者中45.0%接受了辅助化疗。
- 2011年以来切除率和辅助治疗率呈上升趋势。
- 切除组患者更年轻、更多在学术机构治疗、更多远端肿瘤、小细胞癌比例更低。
- 切除组中位总生存29.4个月,未切除组8.6个月(p < 0.001)。
- 调整术前因素的多因素Cox模型显示切除与生存改善相关(aHR 0.58,95%CI 0.37-0.92),辅助治疗无显著关联。
临床怎么用
- 对局限性胰腺神经内分泌癌,可考虑以治愈为目的的手术切除。
- 辅助化疗的决策需个体化,缺乏明确生存获益证据。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 样本量较小(199例),辅助化疗分析效力有限。
- 数据库研究可能缺乏部分混杂因素信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of curative-intent resection and perioperative chemotherapy for nonmetastatic pancreatic neuroendocrine carcinoma (PanNEC) remains unclear due to their biological aggressiveness and rarity. This study aimed to evaluate the association of resection and perioperative chemotherapy with overall survival for nonmetastatic PanNEC. STUDY DESIGN: Patients with localized (cT1-3, M0), small- and large-cell PanNEC were identified in the National Cancer Database from 2004 to 2017. The changing trends in terms of the annual proportions of resection and adjuvant chemotherapy were assessed. The survival of patients who received resection and those who received adjuvant chemotherapy were investigated using Kaplan-Meier estimates and Cox regression models. RESULTS: In total, 199 patients with localized small- and large-cell PanNEC were identified; 50.3% of those were resected, and 45.0% of the resected patients received adjuvant chemotherapy. Rate of resection and adjuvant treatment has trended upward since 2011. The resected group was younger, was more often treated at academic institutions, had more distal tumors, and had a lower number of small-cell PanNEC. The median overall survival was longer in the resected group compared to the unresected group (29.4 months vs 8.6 months, p < 0.001). Resection was associated with improved survival in a multivariable Cox regression model adjusting for preoperative factors (adjusted hazard ratio 0.58, 95% CI 0.37 to 0.92), while adjuvant therapy was not. CONCLUSIONS: This nationwide retrospective study suggests that resection is associated with improved survival in patients with localized PanNEC. The role of adjuvant chemotherapy needs more investigation.
引用
- Sugawara T, Rodriguez Franco S, Franklin O, et al. Management of Localized Small- and Large-Cell Pancreatic Neuroendocrine Carcinoma in the National Cancer Database. J Am Coll Surg. 2023. PMID: 37146214. doi:10.1097/XCS.0000000000000735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。